The use of AI in the health care industry has been dealt a blow after IBM Watson Health announced it was reducing its Watson for Drug Discovery product due to a " lacklustre financial performance " . According to STAT News , sources said IBM will no longer develop or develop the unit , which will remain accessible to existing users , and will instead focus on clinical trial testing . IEEE Spectrum recently spotlighted the paucity of funding from collaborations between medical firms and IBM Watson Health , amid continued uncertainty surrounding the clinical benefits of AI .
The use of AI in the health care industry has been dealt a blow after IBM Watson Health said it was reducing its Watson for Drug Discovery product due to a "lacklustre financial performance". According to STAT News, sources said IBM will no longer market or develop the unit, which will remain accessible to existing users, and will instead focus on clinical trial matching. IEEE Spectrum recently spotlighted the paucity of results from collaborations between medical firms and IBM Watson Health, amid continued uncertainty surrounding the clinical benefits of AI.